Diabetes Mellitus, Type 2  >>  Suglat (ipragliflozin)  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Suglat (ipragliflozin) / EMD Serono, Kotobuki, Astellas
STELLA-ELDER, NCT02297620: The Survey of Ipragliflozin Treatment in Elderly type2 Diabetes Patients

Completed
N/A
8687
Japan
Suglat®, ipragliflozin
Astellas Pharma Inc
Type 2 Diabetes
07/15
07/15
HARUKAS, NCT02317484: Investigation for Clinical Efficacy and Safety of Ipragliflozin 50mg and 100mg on Type II Diabetes

Completed
N/A
231
Japan
Ipragliflozin (SGLT2 inhibitor)
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan, Osaka Saiseikai Nakatsu Hospital, Astellas Pharma Inc
Diabetes Mellitus, Type 2
11/17
02/18
STELLALONGTERM, NCT02479399: Specified Drug Use Results Survey of Ipragliflozin Treatment in type2 Diabetes Patients

Completed
N/A
11412
Japan
ipragliflozin, ASP1941, Suglat
Astellas Pharma Inc
Type 2 Diabetes
10/18
10/18

Download Options